WO2021011871A1 - Agents de dégradation de mertk et leurs utilisations - Google Patents
Agents de dégradation de mertk et leurs utilisations Download PDFInfo
- Publication number
- WO2021011871A1 WO2021011871A1 PCT/US2020/042534 US2020042534W WO2021011871A1 WO 2021011871 A1 WO2021011871 A1 WO 2021011871A1 US 2020042534 W US2020042534 W US 2020042534W WO 2021011871 A1 WO2021011871 A1 WO 2021011871A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nitrogen
- ring
- independently selected
- oxygen
- sulfur
- Prior art date
Links
- 0 CCCCCC1=CC(CCC)*C1 Chemical compound CCCCCC1=CC(CCC)*C1 0.000 description 12
- ISPBCAXOSOLFME-UHFFFAOYSA-N CCOc1c[n](-c(c(C)c2)ccc2F)nc1C(Nc(cc1)cc(F)c1Oc1c(cc(c(OC)c2)OC)c2ncc1)=O Chemical compound CCOc1c[n](-c(c(C)c2)ccc2F)nc1C(Nc(cc1)cc(F)c1Oc1c(cc(c(OC)c2)OC)c2ncc1)=O ISPBCAXOSOLFME-UHFFFAOYSA-N 0.000 description 2
- ZGOKUFQIUANFTO-SRXBLUIQSA-N CC(COC)Nc1ncc(c(-c2ccc(CN3CCN(C)CC3)cc2)c[n]2[C@H](CC3)CC[C@@H]3O)c2n1 Chemical compound CC(COC)Nc1ncc(c(-c2ccc(CN3CCN(C)CC3)cc2)c[n]2[C@H](CC3)CC[C@@H]3O)c2n1 ZGOKUFQIUANFTO-SRXBLUIQSA-N 0.000 description 1
- RYFDFPFHNBONTK-UHFFFAOYSA-N CC(c(cc1)ccc1-c1n[n](C(CC2)CCC2=O)c2nc(NCCC(F)(F)F)ncc12)N1CCN(C)CC1 Chemical compound CC(c(cc1)ccc1-c1n[n](C(CC2)CCC2=O)c2nc(NCCC(F)(F)F)ncc12)N1CCN(C)CC1 RYFDFPFHNBONTK-UHFFFAOYSA-N 0.000 description 1
- XYSYRHAUHUPOHK-MEMLXQNLSA-N CCCCNc1ncc(-c2ccc(CN3CCN(C)CC3)cn2)c(N[C@H](CC2)CC[C@@H]2O)n1 Chemical compound CCCCNc1ncc(-c2ccc(CN3CCN(C)CC3)cn2)c(N[C@H](CC2)CC[C@@H]2O)n1 XYSYRHAUHUPOHK-MEMLXQNLSA-N 0.000 description 1
- UAMYVDBLYXYGJL-HHJDMTGBSA-N CCCCNc1ncc(c(-c2ccc(C(C)N3CCN(CC)CC3)cc2)c[n]2[C@H](CC3)CC[C@@H]3O)c2n1 Chemical compound CCCCNc1ncc(c(-c2ccc(C(C)N3CCN(CC)CC3)cc2)c[n]2[C@H](CC3)CC[C@@H]3O)c2n1 UAMYVDBLYXYGJL-HHJDMTGBSA-N 0.000 description 1
- DULGQHVFUYKHPM-UHFFFAOYSA-N CCCCNc1ncc(c(-c2ccc(CN3CCNCC3)cc2)n[n]2C3CCC(COC(C(C(C)C)=N)=O)CC3)c2n1 Chemical compound CCCCNc1ncc(c(-c2ccc(CN3CCNCC3)cc2)n[n]2C3CCC(COC(C(C(C)C)=N)=O)CC3)c2n1 DULGQHVFUYKHPM-UHFFFAOYSA-N 0.000 description 1
- VNBRGSXVFBYQNN-UHFFFAOYSA-N CCOC(C=CN1c(cc2)ccc2F)=C(C(Nc(cc2)cc(F)c2Oc2ccnc(N)c2Cl)=O)C1=O Chemical compound CCOC(C=CN1c(cc2)ccc2F)=C(C(Nc(cc2)cc(F)c2Oc2ccnc(N)c2Cl)=O)C1=O VNBRGSXVFBYQNN-UHFFFAOYSA-N 0.000 description 1
- QFYOKPXFBKSNQJ-QVYRIUEQSA-N Cc1ccc(CNc2ncc(c(-c3ccc(CN4CCN(C)CC4)cc3)c[n]3[C@H](CC4)CC[C@@H]4O)c3n2)cc1 Chemical compound Cc1ccc(CNc2ncc(c(-c3ccc(CN4CCN(C)CC4)cc3)c[n]3[C@H](CC4)CC[C@@H]4O)c3n2)cc1 QFYOKPXFBKSNQJ-QVYRIUEQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La présente invention concerne des composés, des compositions à base de ceux-ci, et des procédés d'utilisation de ceux-ci.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875266P | 2019-07-17 | 2019-07-17 | |
| US62/875,266 | 2019-07-17 | ||
| US202062959342P | 2020-01-10 | 2020-01-10 | |
| US62/959,342 | 2020-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021011871A1 true WO2021011871A1 (fr) | 2021-01-21 |
Family
ID=74211378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2020/042534 WO2021011871A1 (fr) | 2019-07-17 | 2020-07-17 | Agents de dégradation de mertk et leurs utilisations |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2021011871A1 (fr) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11318205B1 (en) | 2017-12-26 | 2022-05-03 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11685750B2 (en) | 2020-06-03 | 2023-06-27 | Kymera Therapeutics, Inc. | Crystalline forms of IRAK degraders |
| US11707457B2 (en) | 2019-12-17 | 2023-07-25 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11746120B2 (en) | 2019-04-05 | 2023-09-05 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
| US11912682B2 (en) | 2021-01-13 | 2024-02-27 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016105518A1 (fr) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles |
| US20180009815A1 (en) * | 2015-08-12 | 2018-01-11 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| WO2020010210A1 (fr) * | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Agents de dégradation de mertk et leurs utilisations |
-
2020
- 2020-07-17 WO PCT/US2020/042534 patent/WO2021011871A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016105518A1 (fr) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles |
| US20180009815A1 (en) * | 2015-08-12 | 2018-01-11 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| WO2020010210A1 (fr) * | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Agents de dégradation de mertk et leurs utilisations |
Non-Patent Citations (2)
| Title |
|---|
| BONDESON ET AL.: "Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead", CELL CHEMICAL BIOLOGY, vol. 25, 2018, pages 78 - 87, XP055561974, DOI: 10.1016/j.chembiol.2017.09.010 * |
| NUNES JOAO, MCGONAGLE GRANT A., EDEN JESSICA, KIRITHARAN GIRIESHANIE, TOUZET MEGANE, LEWELL XIAO, EMERY JOHN, EIDAM HILARY, HARLIN: "Targeting IRAK 4 for Degradation with PROTACs", ACS MED CHEM LETT., vol. 10, no. 7, 14 June 2019 (2019-06-14), pages 1081 - 1085, XP055785428 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11318205B1 (en) | 2017-12-26 | 2022-05-03 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11723980B2 (en) | 2017-12-26 | 2023-08-15 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11807636B2 (en) | 2018-11-30 | 2023-11-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11746120B2 (en) | 2019-04-05 | 2023-09-05 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11707457B2 (en) | 2019-12-17 | 2023-07-25 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11779578B2 (en) | 2019-12-17 | 2023-10-10 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11685750B2 (en) | 2020-06-03 | 2023-06-27 | Kymera Therapeutics, Inc. | Crystalline forms of IRAK degraders |
| US11912682B2 (en) | 2021-01-13 | 2024-02-27 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230089916A1 (en) | Irak degraders and uses thereof | |
| WO2020010210A1 (fr) | Agents de dégradation de mertk et leurs utilisations | |
| WO2021011868A1 (fr) | Agents de dégradation d'irak et leurs utilisations | |
| EP4076536A1 (fr) | Agents de dégradation d'irak et leurs utilisations | |
| US11591332B2 (en) | IRAK degraders and uses thereof | |
| WO2021011871A1 (fr) | Agents de dégradation de mertk et leurs utilisations | |
| WO2020251969A1 (fr) | Agents de dégradation de smarca et leurs utilisations | |
| WO2020251974A1 (fr) | Inhibiteurs de smarca et leurs utilisations | |
| WO2020251972A1 (fr) | Agents de dégradation de smarca et leurs utilisations | |
| EP3946360A1 (fr) | Agents de dégradation de stat et leurs utilisations | |
| US11679109B2 (en) | SMARCA degraders and uses thereof | |
| WO2021133917A1 (fr) | Inhibiteurs de smarca et leurs utilisations | |
| EP4294790A1 (fr) | Agents de dégradation de smarca et utilisations associées | |
| AU2021358130A1 (en) | Stat degraders and uses thereof | |
| EP4072591A1 (fr) | Agents de dégradation d'irak et leurs utilisations | |
| JP2024513011A (ja) | Ｈｐｋ１アンタゴニスト及びその使用 | |
| EP4259612A1 (fr) | Agents de dégradation de smarca et leurs utilisations | |
| WO2023192586A1 (fr) | Agents de dégradation d'irak et leurs utilisations | |
| WO2023250058A1 (fr) | Agents de dégradation de stat et leurs utilisations | |
| WO2021222366A1 (fr) | Inhibiteurs d'irak et leurs utilisations | |
| WO2024081893A1 (fr) | Formes salines d'agents de dégradation d'irak4 | |
| WO2024064080A1 (fr) | Agents de dégradation de stat6 et leurs utilisations | |
| CN117377673A (zh) | Hpk1拮抗剂和其用途 | |
| CN117915912A (zh) | Hpk1拮抗剂和其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20840235 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20840235 Country of ref document: EP Kind code of ref document: A1 |